CMKLR1 and metabolic dysfunction-associated steatotic liver disease: The alleviating effect on steatosis are only notified in mice with less weight gain, indicating that there is no sufficient evidence to reveal that intestinal chemerin/CMKLR1 pathway is involved in gut-liver axis hence the progress of NAFLD.